Scientific Sessions 2025  /  Drugs and Hypertension – New Treatments Causing Hypertension and New Mechanisms for Treatment  /  Aldosterone synthase inhibitors
Logo

American Heart Association

  43
  0

Final ID:

Aldosterone synthase inhibitors

  • Laffin, Luke  ( Cleveland Clinic Foundation , Cleveland , Ohio , United States )
  • Weir, Matthew  ( UNIVERSITY MARYLAND SCHOOL MED , Lutherville , Maryland , United States )
    • Author Disclosures:
    Luke Laffin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Mineralys:Active (exists now) ; Consultant:Ripple Medical:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Recor:Active (exists now) ; Royalties/Patent Beneficiary:Elsevier:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Crispr Theapeutics:Active (exists now) ; Research Funding (PI or named investigator):Kardigan:Active (exists now) ; Consultant:Astrazeneca:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) | Matthew Weir: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Vera:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Mineralys:Active (exists now) ; Consultant:Corcept:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Bayer:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Drugs and Hypertension – New Treatments Causing Hypertension and New Mechanisms for Treatment

Monday, 11/10/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Treatment of hypertension caused by cancer therapeutics targeting VEGF pathways

Waliany Sarah, Witteles Ronald

Endothelin receptor antagonists

Blazek Olivia, Flack John

More abstracts from these authors:
The Global Risk Consortium. Global effect of CV risk factors on lifetime estimates
2Saxena M, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension

Weir Matthew

Efficacy and Safety of Lorundrostat in Hypertension Patients with High Unmet Medical Need: Subgroup Analyses of the Launch-HTN Trial in Uncontrolled and Treatment-Resistant Hypertension

Saxena Manish, Laffin Luke, Luther James, Weir Matthew, Kopjar Branko, Rodman David

You have to be authorized to contact abstract author. Please, Login
Not Available